Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pharma Foods International Co., Ltd. ( (JP:2929) ) has issued an announcement.
Pharma Foods International reported that the first half of FY2026 was an aggressive investment phase, with strategic upfront spending executed as planned to strengthen its business base and future profitability. The company is redefining its “New Value Creation 1K Project” while reaffirming its ambition to become a high-profit, high-growth biotechnology player.
Despite moderate challenges in new customer acquisition, profitability improved in the first half through higher customer retention and increased lifetime value, especially around its flagship Newmo series. On this basis, the company raised its full-year FY2026 earnings forecast, projecting operating income to exceed initial expectations by 33.3%, and signaled that the second half will shift toward profit generation, margin expansion, and financial foundation strengthening.
Management framed these moves as part of a broader effort to enhance corporate value by connecting innovation-led transformation with capital efficiency and sustainable growth. The reaffirmation of the ¥100 billion revenue milestone and focus on project management underscore a strategy aimed at consolidating its market position and maximizing returns for stakeholders over the medium to long term.
The most recent analyst rating on (JP:2929) stock is a Hold with a Yen648.00 price target. To see the full list of analyst forecasts on Pharma Foods International Co., Ltd. stock, see the JP:2929 Stock Forecast page.
More about Pharma Foods International Co., Ltd.
Pharma Foods International Co., Ltd. operates in the biotechnology and health-related products sector, focusing on value creation through science-driven innovation. The company emphasizes high-profit, high-growth business models rooted in biotechnology, with a long‑term target of reaching ¥100 billion in revenue and enhancing shareholder and corporate value.
Average Trading Volume: 260,744
Technical Sentiment Signal: Sell
Current Market Cap: Yen19.35B
See more data about 2929 stock on TipRanks’ Stock Analysis page.